DEPARTMENT OF HEALTH SERVICES

Division of Health Care Access and Accountability F-01672 (01/2016)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR AMPHETAMINE FORMULATIONS

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Amphetamine Formulations Completion Instructions, F-01672A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Amphetamine Formulations form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I — MEMBER INFORMATION							
1. Name — Member (Last, First, Middle Initial)							
Member Identification Number	3. Date of Birth — Member						
SECTION II — PRESCRIPTION INFORMATION							
4. Drug Name	5. Drug Stre	5. Drug Strength					
6. Date Prescription Written	7. Directions for Use						
8. Name — Prescriber		9. National Provider Identifier (NPI) — Prescriber					
10. Address — Prescriber (Street, City, State, ZIP+4 Code)							
11. Telephone Number — Prescriber							
SECTION III — CLINICAL INFORMATION							
12. Diagnosis Code and Description							
13. Has the member experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction with Vyvanse [®] ? □ Yes □ No							
If yes, list the dose, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction, and the approximate dates that Vyvanse® was taken in the space provided.							

Continued



F-01672 ((01/2016)
-----------	-----------

SECTION III — CLINICAL INFORMATION	(Continued)								
14. Has the member experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction with a preferred stimulant, other than Vyvanse [®] ? □ Yes □ No							No		
If yes, list the preferred stimulant and dose, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction, and the approximate dates the preferred stimulant was taken in the space provided.									
SECTION IV — AUTHORIZED SIGNATURE									
15. SIGNATURE — Prescriber			16. Date Sig	ned					
SECTION V — FOR PHARMACY PROVIDERS USING STAT-PA									
17. National Drug Code (11 Digits) 18. Days' Supply Rec		quested (Up to	365	Days)					
19. NPI									
20. Date of Service (MM/DD/CCYY) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days in the past.)									
21. Place of Service									
22. Assigned PA Number									
23. Grant Date	24. Expiration Date		25. Number of Days Approved						
SECTION VI — ADDITIONAL INFORMATION									
26. Include any additional information in the drug requested may also be included he		al diagnostic and clinic	al information	expl	aining th	ne nee	ed for the		